This research explores a novel CAR-T cell therapy designed to treat solid tumors by targeting the tumor microenvironment rather than cancer cells directly. Scientists engineered armored CAR-T cells to deplete immunosuppressive macrophages—specifically those expressing FOLR2 or TREM2—while simultaneously delivering the potent immune stimulant IL-12. In animal models of ovarian, pancreatic, and lung cancer, this dual approach successfully eliminated pro-tumor macrophages and triggered a surge in endogenous cytotoxic T cells. This reprogramming shifted the tumor's surroundings from a suppressed state to an immunostimulatory one, leading to durable tumor clearance and extended survival. Notably, the study demonstrates that low doses of these armored cells can achieve high efficacy without the severe toxicity or the need for pre-treatment lymphodepletion typically associated with IL-12 therapies.

References:

• Mateus-Tique J, Lakshmi A, Singh B, et al. Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth[J]. Cancer Cell, 2026.